Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy

Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy

2026.01.28
From January 10 to 11, 2026, the Beijing Young Urologic Oncology Physicians Academic Exchange Conference was successfully held in Beijing. The meeting brought together leading experts and young physicians in urologic oncology to discuss cutting-edge scientific advances and key clinical challenges, with the goal of fostering academic innovation and supporting the growth of emerging clinicians.
Professor Ludong Qiao Interprets the IDSA Guidelines on Complicated Urinary Tract Infections: Rational Use of Cefiderocol and Novel Antibiotic Combinations

Professor Ludong Qiao Interprets the IDSA Guidelines on Complicated Urinary Tract Infections: Rational Use of Cefiderocol and Novel Antibiotic Combinations

2026.01.28
The Infectious Diseases Society of America (IDSA) has recently released its Clinical Practice Guidelines for the Treatment and Management of Complicated Urinary Tract Infections (cUTI)—the first IDSA guideline dedicated specifically to cUTI. The updated guideline revises the definition of cUTI and proposes a four-step framework to support individualized empiric treatment decisions.
Professor Yonghong Li: Neoadjuvant Therapy for Locally Advanced Prostate Cancer—A Chinese Perspective and Clinical Balance

Professor Yonghong Li: Neoadjuvant Therapy for Locally Advanced Prostate Cancer—A Chinese Perspective and Clinical Balance

2026.01.28
From January 10 to 11, 2026, the Beijing Young Urologic Oncology Physicians Academic Exchange Conference concluded successfully in Beijing. The meeting brought together leading experts and young physicians in urologic oncology to discuss cutting-edge scientific advances and clinical challenges, with the goal of fostering innovation and professional development among emerging clinicians
Research Breakthrough by Professor Qiang Lü’s Team at Jiangsu Provincial People’s Hospital: Imaging AI Enables Personalized Prognosis Prediction and Treatment Response Assessment in Bladder Cancer

Research Breakthrough by Professor Qiang Lü’s Team at Jiangsu Provincial People’s Hospital: Imaging AI Enables Personalized Prognosis Prediction and Treatment Response Assessment in Bladder Cancer

2026.01.28
Recently, the Department of Urology at Jiangsu Provincial People’s Hospital, led by Professor Qiang Lü, published a multicenter study in EClinicalMedicine (CAS Zone 1, Impact Factor = 10.0). By integrating multicenter MRI data, the research team developed a multimodal fusion–based deep learning model designed to achieve noninvasive preoperative survival prediction in bladder cancer patients.
Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate

Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate

2026.01.25
Radical prostatectomy (RP) remains the primary surgical treatment for localized prostate cancer. However, a substantial proportion of patients experience biochemical recurrence (BCR) following surgery, which is closely associated with disease progression and prostate cancer–specific mortality. Consequently, reducing postoperative BCR and improving long-term outcomes in prostate cancer patients have become major areas of clinical research focus.
Advancing Precision Therapy in Urothelial Carcinoma: A Collaborative Study by Professors Xuesong Li, Qi Tang, Jianhua Zhang, and Xiaoying Li Explores a Novel Approach to HER2 Assessment

Advancing Precision Therapy in Urothelial Carcinoma: A Collaborative Study by Professors Xuesong Li, Qi Tang, Jianhua Zhang, and Xiaoying Li Explores a Novel Approach to HER2 Assessment

2026.01.23
A multidisciplinary team led by Professors Xuesong Li and Qi  Tangfrom the Institute of Urology and Department of Urology, Peking University First Hospital, in collaboration with Professor  Jianhua  Zhang’s team from the Department of Nuclear Medicine and Professor  Xiaoying Li’s team from the Department of Radiation Oncology, has published an original research article in Clinical Nuclear Medicine (Impact Factor: 9.6), the official journal of the Society of Nuclear Medicine and Molecular Imaging.
Disitamab Vedotin–Based Combination Strategy Redefines First-Line Treatment for Advanced Urothelial Carcinoma, Nearly Doubling Overall Survival

Disitamab Vedotin–Based Combination Strategy Redefines First-Line Treatment for Advanced Urothelial Carcinoma, Nearly Doubling Overall Survival

2026.01.23
In 2025, the 15th Shanghai Urologic Oncology Academic Conference was grandly held in Pudong, Shanghai. The meeting brought together leading experts in urologic oncology from China and around the world to engage in in-depth discussions on advances in the diagnosis and treatment of urothelial carcinoma, prostate cancer, renal cell carcinoma, and other major genitourinary malignancies.